Preview

Медицинский алфавит

Расширенный поиск
Доступ открыт Открытый доступ  Доступ закрыт Доступ платный или только для Подписчиков

Место регорафениба в лечении больных метастатическим колоректальным раком: когда все варианты исчерпаны? Или в третьей линии?

https://doi.org/10.33667/2078-5631-2021-19-30-35

Полный текст:

Аннотация

Вопрос применения регорафениба в лечении больных метастатическим колоректальным раком разделяет российских и зарубежных онкологов на два лагеря. Многие специалисты откладывают его назначение до ситуации, когда все другие варианты системной терапии исчерпаны, физическое состояние пациента близко к неудовлетворительному, а метастатический процесс достигает максимального объема. Позиция онкологов, придерживающихся такой позиции, основана на небольшой частоте объективных ответов и невысоких показателях выживаемости без признаков прогрессирования процесса, при наличии свидетельств о наличии большей эффективности повторного назначения уже использованных в лечении данного пациента химио‑ и таргетных препаратов. С другой стороны, анализ мировой литературы, посвященной регорафенибу и вариантам III линии терапии метастатического колоректального рака, показывает неоднозначность вышеуказанного подхода и потенциал препарата с точки зрения улучшения перспектив пациента за счет преодоления резистентности опухолевой массы к уже использованным лекарственным препаратам и возможности предоставить пациенту так называемые химиотерапевтические каникулы.

Об авторах

А. Л. Пылев
ООО «Центр инновационных медицинских технологий»
Россия

Пылев Андрей Львович, к. м. н., главный врач федеральной сети клиник экспертной онкологии «Евроонко»

 г. Москва



А. А. Жандарова
ООО «Центр инновационных медицинских технологий»
Россия

Жандарова Анна Александровна, зав/ онкологическим отделением клиники «Евроонко»

 г. Москва



Д. С. Романов
ООО «Центр инновационных медицинских технологий»; ЧУЗ «Центральная клиническая больница „РЖД-Медицина“»
Россия

Романов Денис Сергеевич, к. м. н., заместитель ген. директора по научной деятельности федеральной сети клиник экспертной онкологии «Евроонко», зав. радиологическим отделением

 г. Москва



В. А. Лисовой
ООО «Центр инновационных медицинских технологий»
Россия

Лисовой Вячеслав Анатольевич, врач‑онколог клиники «Евроонко»

 г. Москва



Список литературы

1. Van Cutsem E, Cervantes A. et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 2016; 27 (8): 1386–1422.

2. McQuade RM, Stojanovska V. Colorectal cancer chemotherapy: the evolution of treatment and new approaches. Curr Med Chem 2017; 24: 1537–1557.

3. Maindrault-Goebel F, Tournigand C. et al. Oxaliplatin reintroduction in patients previously treated with leucovorin, florouracil and oxaliplatin for metastatic colorectal cancer. Ann Oncol 2004; 15 (8): 1210–1214.

4. Tonini G, Imperatori M. et al. Rechallenge therapy and treatment holiday: different strategies in management of metastatic colorectal cancer. J Exp Clin Cancer Res 2013; 32 (1): 92.

5. McLean J, Rho YS. et al. Clinical practice patterns in chemotherapeutic treatment regimens for metastatic colorectal cancer. Clin Colorectal Cancer 2016; 15 (2): 135–140.

6. Nielsen DL, Palshof JA. et al. A systematic review of salvage therapy to patients with metastatic colorectal cancer previously treated with florouracil, oxaliplatin and irinotecan ± targeted therapy. Cancer Treat Rev 2014; 40 (6): 701–715.

7. Network NCC. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Colon Cancer Version 2.2017. Fort Washington, Version 2. 2021. January 21, 2021.

8. Costa T, Nunes J. et al. REOX: evaluation of the effiacy of retreatment with an oxaliplatin-containing regimen in metastatic colorectal cancer: a retrospective single-center study. Clin Colorectal Cancer 2017; 16: 316–323.

9. Besora S, Santos C. et al. Rechallenge with oxaliplatin and peripheral neuropathy in colorectal cancer patients. J Cancer Res Clin Oncol 2018; 144: 1793–1801.

10. Tanioka H, Asano M. et al. Cetuximab retreatment un patients with metastatic colorectal cancer who exhibited a clinical benefi in response to prior cetuximab: a retrospective study. Oncol Lett 2018; 16: 3674–3680.

11. Mauri G, Pizzutilo EG. et al. Retreatment with anti-EGFR monoclonal antibodies in metastatic colorectal cancer: systematic review of different strategies. Cancer Treat Rev 2019; 73: 41–53.

12. Liu X, George GC. et al. Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR response. BMS Cancer 2015; 15: 713.

13. Kajitani T, Makiyama A. et al. Anti-epidermal Growth Factor Receptor antibody readministration in chemorefractory metastatic colorectal cancer. Anticancer Res 2017; 37: 6459–6468.

14. Cremolini C, Rossini D. et al. Rechallenge for patients with RAS and BRAF wild-type metastatic colorectal cancer with acquired resistance to fist-line cetuximab and irinotecan: a phase 2 single-arm clinical trial. JAMA Oncol 2019; 5: 343–350.

15. Grothey A, van Cutsem E. et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013; 381 (9863): 303–12.

16. Li J, Qin S. et al. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2015; 16 (6): 619–629.

17. Van Cutsem E, Martinelli E. et al. Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study. Oncologist. 2019; 24 (2): 185–1 92.

18. Adenis A, de la Fouchardiere C. et al. Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program [published correction appears in BMC Cancer. 2016 Jul 25; 16 (1): 518]. BMC Cancer. 2016; 16: 412. Published 2016 Jul 7. DOI: 10.1186/s12885–016–2440–9.

19. Ducreux M, Petersen LN. et al. Safety and effectiveness of regorafenib in patients with metastatic colorectal cancer in routine clinical practice in the prospective, observational CORRELATE study. Eur J Cancer 2019; 123: 146–154.

20. Tol J, Nagtegaal ID. BRAF mutation in metastatic colorectal cancer. N Engl J Med 2009; 361: 98–99.

21. Van Custem E, Kohne CH. et al. Cetuximab plus irinotecan, florouracil, and leucovorin as fist-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011; 29: 2011–9.

22. Koopman M, Kortman GAM. et al. Defiient mismatch repair system in patients with sporadic advanced colorectal cancer. Br J Cancer 2009; 100: 266–73.

23. Lochhead P, Kuchiba A. et al. Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication. J Natl Cancer Inst 2013; 105: 1151–6.

24. Venderbosch S, Nagtegaal ID. et al. Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO 2, COIN, and FOCUS studies. Clin Cancer Res 2014; 20: 5322–30.

25. Sartore-Bianchi A, Trusolino L. et al. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER 2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncol 2016; 17: 738–46.

26. Sartore-Bianchi A, Amatu A. et al. HER 2 positivity predicts unresponsiveness of EGFR-targeted treatment in metastatic colorectal cancer. Oncologist 2019.

27. U. S. Food & Drug Administration. Package Insert. STIVARGA (regorafenib) tablets, for oral use. 2020.

28. Bendell JC, Rosen LS. et al. Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer [published correction appears in Cancer Chemother Pharmacol. 2016 Feb; 77 (2): 439]. Cancer Chemother Pharmacol. 2015; 76 (5): 925–932. DOI: 10.1007/s00280–015–2850–4.

29. Yoshino T, Mizunuma N. et al. TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial. Lancet Oncol. 2012 Oct; 13 (10): 993–1001. DOI: 10.1016/S 1470–2045(12)70345–5. Epub 2012 Aug 28.

30. Mayer RJ, Van Cutsem E. et al; RECOURSE Study Group. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med. 2015 May 14; 372 (20): 1909–19. DOI: 10.1056/NEJMoa1414325. PMID: 25970050.

31. Tonini G, Imperatori M. Rechallenge therapy and treatment holiday: different strategies in management of metastatic colorectal cancer. J Exp Clin Can Res: CR 2013; 32: 92.

32. Karani A, Felismino TC. et al. Is there a role for rechallenge and reintroduction of anti-EGFR plus chemotherapy in later lines of therapy for metastatic colorectal carcinoma? A retrospective analysis. Ecancer 2020, 14: 1069. https://doi.org/10.3332/ecancer.2020.1069.

33. Grothey A, Ciardiello F. How to Incorporate a Chemo-Free Interval Into the Management of Metastatic Colorectal Cancer. Clinical Advances in Hematology & Oncology October 2020. Volume 16, Issue 10, Supplement 16.

34. Tournigand C, André T. et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004; 22 (2): 229–237.

35. Loupakis F, Cremolini C. et al. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med. 2014; 371 (17):1609–1618.

36. Cremolini C, Antoniotti C. et al. Updated results of TRIBE2, a phase III, randomized strategy study by GONO in the fist- and second-line treatment of unresectable mCRC [ASCO abstract 3508]. J Clin Oncol. 2019; 37 (15 suppl).

37. Parseghian CM, Loree JM. et al. Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge. Ann Oncol. 2019 Feb 1; 30 (2): 243–249. DOI: 10.1093/annonc/mdy509. PMID: 30462160; PMCID: PMC6657008.

38. Cerchiaro E, Squadroni M. et al. Intermittent maintenance treatment with bevacizumab in patients with metastatic colorectal cancer: a single centre experience [ASCO GI abstract 776]. J Clin Oncol. 2017; 35 (suppl 4S).

39. Chibaudel B, Tournigand C. et al. Platinum-sensitivity in metastatic colorectal cancer: towards a defiition. Eur J Cancer. 2013; 49 (18): 3813–3820.

40. Shitara K, Yamanaka T. et al. REVERCE: a randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for previously treated metastatic colorectal cancer patients. Ann Oncol. 2019; 30 (2): 259–265.

41. Kidd MT, Wilcox RE. et al. Effiacy of chemotherapy after treatment with regorafenib in metastatic colorectal cancer (mCRC). JCO 2015; 36 (Suppl 3S): Abstract 678.

42. Marks EI, Tan C. et al. Regorafenib with a floropyrimidine for metastatic colorectal cancer after progression on multiple 5-FU-containing combination therapies and regorafenib monotherapy. Cancer Biol Ther 2015; 16 (12): 1710–1 719.

43. Lu CY, Yeh YS. et al. FOLFIRI and regorafenib combination therapy with dose escalation of irinotecan as fourth-line treatment for patients with metastatic colon cancer according to UGT1A1 genotyping. Onco Targets Ther 2014; 7: 2143–2146.

44. Napolitano S, Martini G. et al. Primary and acquired resistance of colorectal cancer to anti-EGFR monoclonal antibody can be overcome by combined treatment of regorafenib with cetuximab. Clin Cancer Res 2015; 21 (13): 2975–2983.

45. Vogel A, Hofheinz RD. Treatment decisions in metastatic colorectal cancer–Beyond fist and second line combination therapies. Cancer Treatment Reviews 2017; 59: 54–60. http://dx.doi.org/10.1016/j.ctrv.2017.04.0070305–7372

46. Трякин АА, Федянин МЮ, и др. Микросателлитная нестабильность как уникальная характеристика опухолей и предиктор эффективности иммунотерапии. Злокачественные опухоли 2019; 9 (4): 59–69.

47. Eng C, Kim TW. et al; IMblaze370 Investigators. Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol. 2019; 20 (6): 849–861.

48. Tai CC, Chen WS. et al. Comparing late-line treatment sequence of regorafenib and reduced-intensity FOLFOXIRI for refractory metastatic colorectal cancer. Am J Clin Oncol. 2020; 43 (1): 28–34.

49. Артамонова ЕВ. Поздние линии терапии метастатического колоректального рака в условиях COVID-19: начать нельзя откладывать (где поставить запятую?). Медицинский алфавит: диагностика и онкотерапия 2020; 29: 3–9.

50. Hu Z, Li Z. et al. Multi-cancer analysis of clonality and the timing of systemic spread in paired primary tumors and metastases. Nature Genetics 2020; 52: 701–8.

51. Bertucci F, Finetti P. et al. Comparative genomic analysis of primary tumors and metastases in breast cancer. Oncotarget 2016; 7 (19): 27208–19.


Рецензия

Для цитирования:


Пылев А.Л., Жандарова А.А., Романов Д.С., Лисовой В.А. Место регорафениба в лечении больных метастатическим колоректальным раком: когда все варианты исчерпаны? Или в третьей линии? Медицинский алфавит. 2021;(19):30-35. https://doi.org/10.33667/2078-5631-2021-19-30-35

For citation:


Pylev A.L., Zhandarova A.A., Romanov D.S., Lisovoy V.A. Place of regorafenib in treatment of patients with metastatic colorectal cancer: when are all options exhausted? Or in third line? Medical alphabet. 2021;(19):30-35. (In Russ.) https://doi.org/10.33667/2078-5631-2021-19-30-35

Просмотров: 117


ISSN 2078-5631 (Print)